The drug is marketed under the name Acomplia has mental health risks, according to several recent studies The French pharmaceutical group Sanofi-Aventis announced the suspension of clinical trials of its slimming drug Rimonabant, which poses risks to the mental health of those who have used it, according to several recent studies. In a statement, Sanofi-Aventis said the decision to end the testing of this product, marketed as Acomplia, has been taken after the "recent demands of certain national health authorities. In that context, had been "compromised" the realization of "global clinical development program" of this medication. He advanced that you will inform health professionals and that each of the persons participating in trials should consult their "clinical investigator" to "discuss their treatment." The French drug maker, stressing that this

announcement does not change their outlook for success for this year, had withdrawn from sale this product provisionally on 23 October, after the European Medicines Agency (EMEA) has requested the suspension of approval on the grounds that may cause psychiatric disorders. The Federal Food and Drug Administration had warned in June 2007 that patients who had taken were more prone to suicidal thoughts. A scientific study published a year ago was evidence that treatment with Acomplia increases the risk of episodes of mental disorder such as depression or anxiety in patients who so far had had no precedent for this type of mental disorders.

We have a solution of your problem, Just click on link given below and Buy Rimonabant online from our online medication shop.
Order rimonabant